Changing perspectives in diabetes: their impact on its classification

被引:22
作者
Wilkin, T. J. [1 ]
机构
[1] Peninsula Med Sch, Dept Endocrinol & Metab, Plymouth, Devon, England
关键词
aetiology; accelerator hypothesis; classification; clinical trial; insulin resistance; type; 1; diabetes;
D O I
10.1007/s00125-007-0665-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Type 1 and type 2 diabetes are usually regarded as distinct disorders, but the convergence of their phenotypes over recent years, the relationship of body weight to the risk of type 1 diabetes, the diminishing importance of the type 1 susceptibility genes and the finding of autoantibodies in patients with type 2 diabetes, invite a different interpretation. The possibility that type I and type 2 diabetes, rather than being different, are merely poles of a single spectrum, where variation in the tempo of beta cell loss determines age at onset and symptoms at presentation, has important implications. Correct classification is crucial because it directs appropriate treatment and, where available, prevention. This article argues that type I diabetes is currently misclassified, provides evidence that insulin resistance drives type 1 diabetes as it does type 2, and proposes how the 'accelerator hypothesis' can be tested in a randomised controlled trial, which could demonstrate, for the first time, the safe and effective prevention of type I diabetes.
引用
收藏
页码:1587 / 1592
页数:6
相关论文
共 50 条
[1]   The stages of type 1A diabetes [J].
Babaya, N ;
Nakayama, M ;
Eisenbarth, GS .
AUTOIMMUNE DISEASES AND TREATMENT: ORGAN-SPECIFIC AND SYSTEMIC DISORDERS, 2005, 1051 :194-204
[2]  
BAUM JD, 1975, LANCET, V2, P866
[3]   Increasing body weight predicts the earlier onset of insulin-dependant diabetes in childhood: testing the 'accelerator hypothesis' (2) [J].
Betts, P ;
Mulligan, J ;
Ward, P ;
Smith, B ;
Wilkin, T .
DIABETIC MEDICINE, 2005, 22 (02) :144-151
[4]   Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk [J].
Bingley, PJ ;
Gale, EAM .
DIABETOLOGIA, 2006, 49 (05) :881-890
[5]   ISLET-CELL ANTIBODIES IN DIABETES-MELLITUS WITH AUTOIMMUNE POLY-ENDOCRINE DEFICIENCIES [J].
BOTTAZZO, GF ;
FLORINCH.A ;
DONIACH, D .
LANCET, 1974, 2 (7892) :1279-1283
[6]   Autoimmunity to islet proteins in children diagnosed with new-onset diabetes [J].
Brooks-Worrell, BM ;
Greenbaum, CJ ;
Palmer, JP ;
Pihoker, C .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (05) :2222-2227
[7]   Association between infant growth before onset of juvenile type-1 diabetes and autoantibodies to IA-2 [J].
Bruining, GJ .
LANCET, 2000, 356 (9230) :655-656
[8]   Peptidomics biomarker discovery in mouse models of obesity and type 2 diabetes [J].
Budde, P ;
Schulte, L ;
Appel, A ;
Neitz, S ;
Kellmann, M ;
Tammen, H ;
Hess, R ;
Rose, H .
COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2005, 8 (08) :775-781
[9]   Prevalence of overweight and obese children between 1989 and 1998: population based series of cross sectional studies [J].
Bundred, P ;
Kitchiner, D ;
Buchan, I .
BMJ-BRITISH MEDICAL JOURNAL, 2001, 322 (7282) :326-328
[10]   AGE-DEPENDENT HLA GENETIC-HETEROGENEITY OF TYPE-1 INSULIN-DEPENDENT DIABETES-MELLITUS [J].
CAILLATZUCMAN, S ;
GARCHON, HJ ;
TIMSIT, J ;
ASSAN, R ;
BOITARD, C ;
DJILALISAIAH, I ;
BOUGNERES, P ;
BACH, JF .
JOURNAL OF CLINICAL INVESTIGATION, 1992, 90 (06) :2242-2250